Clinical Trial Update: Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on thymalfasin (thymosin alpha-1) as adjuvant therapy after curative resection in HBV-related hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Thymalfasin (thymosin alpha-1)

Snippet

Sponsor: Jia Fan | Conditions: Curable Hepatitis B Virus-Related Hepatocellular Carcinoma | Phase 4 | Status: UNKNOWN